AN
$3.81
-0.05
(-1.30%)
As of Oct 22, 2026, 9:33 PM EDT · cached
Price history
Annexon Inc (ANNX) is trading down at $3.81 (-1.30%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: July 24, 2020 · $17.00 offering · NASDAQ · View IPO details →
Annexon Inc net income history (FY2019–FY2025)
Net income
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Operating income | −$32.5M | −$63.5M | −$130.7M | −$145.6M | −$143.7M | −$154.1M | −$216.4M |
| Net income | −$37.2M | −$63.4M | −$130.3M | −$141.9M | −$134.2M | −$138.2M | −$206.7M |
| EPS (diluted) | −$88.30 | −$4.15 | −$3.40 | −$2.60 | −$1.77 | −$1.01 | −$1.34 |
| Balance sheet | |||||||
| Cash and equivalents | $43.9M | $268.6M | $74.8M | $140.0M | $225.1M | $49.5M | $162.1M |
| Total assets | $49.9M | $355.9M | $287.0M | $285.1M | $297.7M | $350.1M | $277.6M |
| Total liabilities | $6.37M | $11.7M | $55.1M | $53.9M | $47.1M | $57.0M | $65.9M |
| Shareholders' equity | −$100.5M | $344.3M | $231.9M | $231.2M | $250.6M | $293.1M | $211.6M |
| Cash flow | |||||||
| Operating cash flow | −$28.4M | −$53.1M | −$106.1M | −$116.3M | −$121.1M | −$118.0M | −$186.4M |
| Capital expenditure | $267.0K | $464.0K | $1.65M | $6.53M | $193.0K | $15.0K | $137.0K |
| Free cash flow | −$28.6M | −$53.6M | −$107.8M | −$122.8M | −$121.3M | −$118.0M | −$186.5M |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$39.4M | −$52.5M | −$57.4M | −$51.7M | −$57.0M | −$50.3M | −$46.1M | −$57.2M |
| Net income | −$34.8M | −$48.6M | −$54.4M | −$49.2M | −$54.9M | −$48.3M | −$44.1M | −$55.3M |
| EPS (diluted) | −$0.25 | −$0.32 | −$0.37 | −$0.34 | −$0.37 | −$0.26 | −$0.23 | −$0.28 |
| Balance sheet | ||||||||
| Cash and equivalents | $79.5M | $49.5M | $97.1M | $132.3M | $139.4M | $162.1M | $175.2M | $199.3M |
| Total assets | $378.8M | $350.1M | $303.0M | $264.6M | $229.1M | $277.6M | $262.9M | $246.1M |
| Total liabilities | $47.2M | $57.0M | $59.2M | $65.6M | $67.7M | $65.9M | $58.4M | $60.0M |
| Shareholders' equity | $331.6M | $293.1M | $243.8M | $199.0M | $161.4M | $211.6M | $204.5M | $186.1M |
| Cash flow | ||||||||
| Operating cash flow | −$32.0M | −$36.0M | −$50.1M | −$38.1M | −$52.3M | −$45.9M | −$46.8M | −$48.0M |
| Capital expenditure | — | $6.00K | $74.0K | $15.0K | $48.0K | $0 | $0 | $137.0K |
| Free cash flow | — | −$36.0M | −$50.1M | −$38.1M | −$52.4M | −$45.9M | −$46.8M | −$48.1M |
From Annexon Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Annexon Inc
- Headquarters
- Brisbane, California From SEC filings, Oct 2026
Recent News (2)
-
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflamm…
-
Annexon adds month 24 endpoint to phase 3 dry AMD trial
Annexon adds month 24 endpoint to phase 3 dry AMD trial
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International